A multi-center randomized phase II study to evaluate the combination therapy of substitution of antiandrogens and tegafur-uracil for castration resistant prostate cancer

Trial Profile

A multi-center randomized phase II study to evaluate the combination therapy of substitution of antiandrogens and tegafur-uracil for castration resistant prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Tegafur/uracil (Primary) ; Antiandrogens
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2012 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2011 Updated results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 15 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top